SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 405554-55-4
- Formula: C27H27N5O2
- Molecular Weight:453.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Braf |
SB-590885 GMP (1 μM; 12 d) increases the cell number by more than 10-fold compared with the control group in erythroid differentiation culture of UCB-CD34+ hematopoietic stem/progenitor cells, while transiently delaying the erythroid differentiation process[1].
SB-590885 GMP (1 μM; 14 d) significantly increases the area of BFU-E erythroid colonies and the total number of erythroid cells, without affecting the proportion of colonies of other lineages. It also alleviates ineffective erythropoiesis caused by cytokine deprivation, reduces apoptosis, and promotes cell proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary human umbilical cord blood CD34+ hematopoietic stem and progenitor cells (UCB-CD34+ HSPCs); Primary human peripheral blood mononuclear cells (PBMCs) from healthy donors
-
Concentration:1 μM
-
Incubation Time:14 days
-
Result:After 7 days of treatment in UCB-CD34+ HSPCs erythroid differentiation culture, it significantly promoted the proliferation of erythroid progenitor cells and enhanced cell viability.
After 9 days of treatment in healthy donor PBMCs erythroid differentiation culture, it markedly promoted erythroid proliferation.
After 12 days of treatment in UCB-CD34+ HSPCs culture, it increased the cell number by more than 10-fold compared with the control group, and temporarily delayed erythroid differentiation.
After 14 days of treatment in UCB-CD34+ HSPCs culture, it achieved 281516-fold cell expansion, while the control group only achieved 16573-fold expansion; and also alleviated ineffective erythropoiesis and promoted cell proliferation under cytokine-restricted conditions.
Chemical Information
-
CAS No. 405554-55-4
-
Molecular Weight 453.54
-
Formula C27H27N5O2
-
SMILES
O/N=C1CCC2=CC(C3=C(NC(C4=CC=C(C=C4)OCCN(C)C)=N3)C5=CC=NC=C5)=CC=C/12
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Wu S, et al. BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling. Signal Transduct Target Ther. 2024;9(1):338. Published 2024 Dec 2. [Content Brief]
[2]. King AJ, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006;66(23):11100-11105. [Content Brief]
[3]. Chen Z, et al. Pan-Cancer Analysis of the TRP Family, Especially TRPV4 and TRPC4, and Its Expression Correlated with Prognosis, Tumor Microenvironment, and Treatment Sensitivity. Biomolecules. 2023;13(2):282. Published 2023 Feb 2. [Content Brief]
[4]. Ruan D, et al. Establishment of human expanded potential stem cell lines via preimplantation embryo cultivation and somatic cell reprogramming. Nat Protoc. 2025;20(10):2698-2734. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SB-590885 (GMP) Related Classifications
HY-10966G Related Classifications
Powered by Bioz